NCT05674669View on ClinicalTrials.gov

A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 20, 2015

Primary Completion Date

July 26, 2016

Study Completion Date

July 17, 2017

Conditions
Healthy
Interventions
DRUG

Lysergic Acid Diethylamide (LSD) 50µg

DRUG

Lysergic Acid Diethylamide (LSD) 75µg

DRUG

Lysergic Acid Diethylamide (LSD) 100µg

DRUG

Placebo/Lysergic Acid Diethylamide (LSD) 75µg

DRUG

Lysergic Acid Diethylamide (LSD) 50µg/75µg

Trial Locations (1)

Unknown

PAREXEL, Early Phase Clinical Unit, London

Sponsors
All Listed Sponsors
lead

Eleusis Therapeutics

INDUSTRY

NCT05674669 - A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers | Biotech Hunter | Biotech Hunter